Not Yet Recruiting PHASE1 INTERVENTIONAL 1-arm NCT06981806

Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal Adenocarcinoma

IIT2023-07-Osipov-CXCR4: Phase I Dose Escalation and Dose Expansion Study of Combination Immunotherapy With Cosibelimab and CXCR4 Inhibition With Balixafortide in Metastatic Treatment Refractory Pancreatic Ductal Adenocarcinoma

Sponsor: Arsen Osipov

Conditions Metastatic Pancreatic Ductal Adenocarcinoma

Interventions Balixafortide Cosibelimab

Updated 3 times since 2025 Last updated: Nov 17, 2025 Started: Jan 31, 2026 Primary completion: Feb 28, 2027 Completion: Feb 28, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06981806, this PHASE1 trial focuses on Metastatic Pancreatic Ductal Adenocarcinoma and remains actively recruiting participants. Sponsored by Arsen Osipov, it has been updated 3 times since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

3 versions recorded

Dec 2025 — Present [monthly]

Not Yet Recruiting PHASE1
Oct 2025 — Dec 2025 [monthly]

Not Yet Recruiting PHASE1
Jun 2025 — Oct 2025 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Arsen Osipov

Data source: Cedars-Sinai Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Los Angeles, United States